Nascent Biotech Inc (CE) (NBIO) Börsenkurse

Nascent Biotech is a clinical stage bio-pharmaceutical company whose Investigational New Drug (IND) application was cleared in December 2018, by the US Food and Drug Administration (FDA),and has completed Phase I human trials on brain cancer patients with its monoclonal antibody product Pritumumab. ... Nascent Biotech is a clinical stage bio-pharmaceutical company whose Investigational New Drug (IND) application was cleared in December 2018, by the US Food and Drug Administration (FDA),and has completed Phase I human trials on brain cancer patients with its monoclonal antibody product Pritumumab. The Company has submitted to the FDA for clearance to begin phase 2 clinical trials. . The objective of the Phase 2 human clinical trial is to assess potential efficacy in reducing the size or eliminating brain tumors, both primary and metastatic. Nascent is focused on developing Pritumumab for the treatment of patients with brain cancer malignancies such as Gliomas and Astrocytoma's. Current therapeutic strategies include chemotherapy, radiation and/or surgery. There exists a need to develop safer more effective drugs and treatment options for this deadly cancer. Mehr anzeigen